Search Results for “Alzheimer” – Page 10 – media

Researchers reveal brain parasites could be used to treat cognitive disorders

Researchers from the University of Glasgow, in collaboration with Tel Aviv University, along with international researchers, have revealed that brain parasites could be used to deliver drugs to the brain to treat cognitive disorders. In the study published in Nature Microbiology, researchers explored whether the common brain parasite Toxoplasma gondii could be used to deliver treatment across the blood-brain barrier, a major complication for the treatment of many neurological conditions. According to a study published in the Lancet Neurology in March and funded by the Bill & Melinda Gates Foundation, neurological conditions are considered the leading cause of ill health worldwide, with stroke, neonatal encephalopathy, migraine, Alzheimer’s disease (AD) and other dementias, and diabetic neuropathy being the biggest global contributors. Researchers engineered Toxoplasma gondii parasites to deliver the MeCP2 protein, a therapeutic protein that has been dubbed a promising target for Rett syndrome, a debilitating neurological disorder caused by mutations in ...
- Source: drugdu
- 62
- August 8, 2024
Jade Bio’s Launch, Brenig’s Debut, Confo’s Cash & More

Recent financing news includes several companies raising money to advance their research to the clinic. Here’s a look back at funding rounds from companies such as Outpace Bio, GRO Biosciences, and Confo Therapeutics. By Frank VinluanOne challenge for developing drugs for autoimmune diseases is that biologic therapies can spark an immune response against them. Immunology and inflammation research is coming up with new approaches to reduce the risk of such responses. That science is progressing in the hands of new companies raising fresh rounds of capital. Inflammation and immunology figures prominently in recent funding news, which includes several companies approaching the clinic with novel biologic drugs. Here’s a recap of recent biotech financings, grouped according to therapeutic area: Immunology & Inflammation —Abiologics unveiled an artificial intelligence-driven platform technology for designing novel biologic drugs based on non-standard amino acids. The startup, which has been incubating within Flagship Pioneering for the past ...
- Source: drugdu
- 91
- August 6, 2024
Cutting-Edge AI Analyzes Blood Samples to Predict Disease 10 Years Before Diagnosis

Scientists have developed an advanced artificial intelligence (AI) approach that can predict the likelihood of developing age-related conditions such as Alzheimer’s and heart disease up to a decade before symptoms manifest. By analyzing blood samples from over 45,000 individuals using machine learning, researchers identified specific protein patterns associated with an increased risk of disease. This capability to predict the probability of developing a health condition before any symptoms are observed could potentially enhance personalized medicine by providing early warnings, thereby opening doors for preventative interventions. Researchers from the University of Edinburgh (Edinburgh, UK) participated in a study that used data from the UK Biobank, which contains genetic and health information from half a million UK participants. They applied AI and machine learning to detect protein patterns in blood that correlate with the onset of common ailments including Alzheimer’s, heart disease, and type 2 diabetes. The analysis was based on medical ...
- Source: drugdu
- 65
- August 3, 2024
MIT study reveals how specific cells in AD become vulnerable and resilient

The neurodegenerative condition is recognised as the most common form of dementia A study conducted by researchers at the Massachusetts Institute of Technology (MIT) has revealed how specific cells and circuits become vulnerable and resilient to cognitive decline in Alzheimer’s disease (AD), despite clear signs of disease pathology. Published in Nature, researchers measured gene expression differences using single-cell RNA profiling in more than 1.3 million cells of over 70 different cell types in six brain regions, including the prefrontal cortex, entorhinal cortex and hippocampus, from 48 tissues donated by the Religious Order Study and the Rush Memory and Aging Project at Rush University, 26 of whom had died with an AD diagnosis and 22 of whom had not. Currently the most common form of dementia, AD is a neurodegenerative condition that deteriorates the brain’s memory and thinking skills. Researchers found that one type of excitatory neuron in the hippocampus and four ...
- Source: https://ramaonhealthcare.com/mit-study-reveals-how-specific-cells-in-ad-become-vulnerable-and-resilient/
- 104
- August 1, 2024
Study suggests targeting amyloid beta production could be promising in AD

A study led by the UK Dementia Research Institute (UK DRI) and University College London (UCL) has suggested targeting amyloid beta production in one cell type in the brain could improve early disease outcomes, with fewer side effects, in Alzheimer’s disease (AD). Published in the journal PLOS Biology, findings suggest that targeting the production of amyloid beta specifically from oligodendrocytes could be a promising therapeutic strategy for treating the neurodegenerative condition. Currently the most common cause of dementia, AD is a progressive, neurodegenerative disease that causes the brain to shrink and brain cells to die. Accumulation of misfolded amyloid beta is recognised as one of the hallmarks of AD, which is believed to be caused by neurons. Researchers aim to test whether oligodendrocytes, a neural cell that produces myelin, the insulating material that surrounds the projections that transfer impulses between neurons, called axons, could produce harmful amyloid beta and whether ...
- Source: drugdu
- 73
- July 30, 2024
KCL study finds cell ageing could reveal early signs of neurodegenerative disease

Researchers from King’s College London (KCL), along with other collaborators, have found that ageing cells could reveal early signs of neurodegenerative diseases, including Alzheimer’s disease or amyotrophic lateral sclerosis. Published in Aging Cell, the findings could provide a wider picture of a target area for drugs and could improve treatments for these types of conditions. Affecting more than one million people in the UK, neurodegenerative conditions, such as multiple sclerosis and Parkinson’s disease, occur when cells of the central nervous system stop working or die. Using fluorescence to measure the viscosity of neuronal cytoplasm, the fluid enclosed by the cell membrane of the neuron, in mice, researchers found that the viscosity of the cytoplasm in the neuron (soma) increased as the mice aged. However, it did not increase in the cytoplasm of the axon, a tail-like structure that transmits electrical and chemical signals to other cells. Researchers suggested that the ...
- Source: drugdu
- 61
- July 30, 2024
FDA Clears Positrigo’s NeuroLF Brain PET System for the Diagnosis of Multiple Brain Disorders

By Don Tracy, Associate Editor Clearance of the NeuroLF Brain PET system marks Positrigo’s first device of its kind to be approved in the United States.The FDA has granted clearance to Positrigo’s NeuroLF brain positron emission tomographic (PET) system, which the company said represents a major advancement in functional brain imaging. The device is designed to diagnose and monitor brain disorders such as Alzheimer disease, brain tumors, epilepsy, and Parkinson disease. As the company’s first brain PET system approved in the United States, Positrigo is currently preparing for global market expansion, with European regulatory approval anticipated later this year.1 “It is not the first device of its kind which receives market clearance in the US, but we believe that our patient-centric and customer-driven design and development efforts over the last couple of years, brought us into the pole position to offer the best imaging solution to address the increased demand ...
- Source: drugdu
- 83
- July 20, 2024
Innovate UK grants £4m to four companies to evaluate biomarkers for dementia

The progressive neurodegenerative disease affects more than 55 million people globally Innovate UK has awarded £4m through its Contracts for Innovation to four UK companies for research into dementia diagnosis. As part of the Bio-Hermes-002 study led by the US-based Global Alzheimer’s Platform Foundation (GAP) in partnership with Novo Nordisk, the organisations will evaluate blood-based and digital innovative biomarkers for the neurological condition. Affecting more than 55 million people globally, which is expected to triple by 2050, dementia is a neurodegenerative condition that affects the ability to remember, think or make decisions in everyday life. The study aims to explore whether these biomarkers can predict the extent of tau and amyloid brain pathology and potentially provide more efficient and less invasive alternatives to the current gold standard for dementia diagnoses: positron emission tomography brain imaging. The project will involve 1,000 participants who are cognitively normal, have mild cognitive impairment or ...
- Source: https://www.ukri.org/news/uk-and-us-join-forces-to-tackle-dementia-with-innovative-biomarkers/
- 92
- July 17, 2024
FDA Says ‘No’ to Novo Nordisk’s Once-Weekly Insulin

The FDA rejected Novo Nordisk’s biologics license application for icodec, citing questions about the manufacturing process for this once weekly insulin as well as its use by type 1 diabetes patients. But there are several high-profile FDA approvals in our recap of recent regulatory news. By Frank VinluanNovo Nordisk’s bid to bring diabetes patients a less burdensome dosing regimen has encountered a setback. The FDA turned down the company’s application for icodec, a slow-acting insulin the company designed for once-weekly dosing as an alternative to daily insulin injections. According to Novo Nordisk, the FDA’s complete response letter raised questions about icodec’s manufacturing process as well as the use of the product in patients with type 1 diabetes. In May, an FDA advisory committee concluded that the available data were not sufficient to show that icodec’s benefits outweigh its risks in type 1 diabetes. Some committee members expressed concerns about icodec’s ...
- Source: drugdu
- 98
- July 16, 2024
Researchers awarded £1.5m for national dementia inequalities network

The ESRC EquaDem Network Plus aims to improve disparities in diagnosis and care Dementia researchers from the University of Liverpool have been awarded £1.5m to establish the first-ever national network for dementia inequalities in diagnosis and care. The new network is just one of four dementia networks that have benefited from £5.5m funding from the Alzheimer’s Society, the Economic and Social Research Council (ESRC) and the National Institute for Health and Care Research (NIHR). Affecting more than 944,000 people in the UK, dementia is a neurodegenerative condition that affects the ability to remember, think or make decisions in everyday life. For those living with the condition, as well as their unpaid carers, many inequalities can often be faced when accessing care and obtaining an assessment and diagnosis. The University of Liverpool’s Institute of Population Health’s senior research fellow, Dr Clarissa Giebel, will lead the network in collaboration with Dame Louise ...
- Source: drugdu
- 104
- July 16, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.